Top 5 This Week

spot_img

Related Posts

Blood Cancer Vaccine Cuts Death Risk by 41% in Trial

Blood Cancer Vaccine Cuts Death Risk by 41% in Trial

A new blood cancer vaccine cut the risk of death by 41% in a late-stage trial, results announced this week show. The vaccine, galinpepimut-S (GPS), was tested in 126 patients with acute myeloid leukaemia (AML) whose cancer had come back after earlier treatment.

Patients on the vaccine lived a median of 24 months, against 14.7 months on the best available treatment. The gap of about nine months met the trial’s main goal, with a hazard ratio of 0.59 and a p-value of 0.035.

Blood cancer vaccine: what the trial tested

REGAL was a global, randomised, open-label Phase 3 study, registered as NCT04229979. It enrolled 126 patients and assigned them one to one to GPS alone or to the investigator’s choice of best available treatment.

The patients had leukaemia that returned after earlier treatment, but had reached another remission with salvage therapy. They could not have a donor stem cell transplant, the standard curative option, which left them with few maintenance options.

The analysis took place after 80 deaths, as the trial plan required. SELLAS announced the topline results on 17 November 2026, with full findings to follow at a medical conference.

How the vaccine works

GPS does not prevent cancer. It is a treatment vaccine for patients already in remission, training the immune system to attack leukaemia cells left behind after chemotherapy. It is built from four peptides derived from WT1, a protein in the cancer cells of more than 95% of people with AML, and it is made in advance, so it needs no separate formulation for each patient.

GPS was developed in Dr David A. Scheinberg’s laboratory at Memorial Sloan Kettering Cancer Center in New York, which licensed it to SELLAS. The centre confirmed the result.

What the results do and do not prove

The 41% figure needs care: it is relative risk, not absolute risk. A hazard ratio of 0.59 means the risk of death at any point was 41% lower in the vaccine group than in the group on best available treatment. In plain terms, the typical patient on the vaccine lived about nine months longer.

The result is real but early: only topline figures have been released, and the findings have not yet been peer reviewed. The trial was small, with 126 patients, and covered only AML patients in a second or later remission who could not have a transplant. It says nothing about other blood cancers.

Side effects were mostly mild to moderate, led by injection-site reactions. Full safety data have not yet been published.

SELLAS plans to meet the US Food and Drug Administration about an accelerated filing route, with a licence application to follow in the first half of 2027. The vaccine stays investigational.

What it means for Pakistan

For Pakistani patients, the result is hopeful but distant: new treatments take years to reach Pakistan, and cost puts many out of reach. Leukaemia care at home still faces basic supply problems.

Feature Pakistan reported this month that Punjab ordered fast supply of nilotinib for more than 3,200 leukaemia patients at six hospitals, after home delivery broke down in June. That medicine treats chronic myeloid leukaemia, a different, slower-growing form of the disease, but the episode shows the same gap: even established treatments can fail to reach patients.

Punjab is building a Rs10 billion cancer hospital in Lahore, with two hospital projects worth Rs11.65 billion also approved. Yet the system is stretched: Khyber Pakhtunkhwa has only 8,024 doctors for more than 40 million people.

The GPS result points to a direction worth watching: maintenance vaccines could one day matter as much as new drugs, if they reach patients at a price health systems can afford. Until then, know the early signs of cancer, seek care early, and ask your own doctor about any new treatment.

Frequently asked questions

What is galinpepimut-S?

An investigational vaccine, also called GPS, that trains the immune system to attack leukaemia cells carrying the WT1 protein, tested as a maintenance treatment for acute myeloid leukaemia.

Which patients were in the trial?

126 patients with acute myeloid leukaemia in a second or later remission, who could not have a donor stem cell transplant.

Does the vaccine prevent blood cancer?

No. It is a treatment vaccine for patients already in remission, aimed at stopping the cancer returning, not preventing it in healthy people.

Is the vaccine available now?

No. It is investigational. SELLAS plans to meet the US FDA, with a licence application to follow in the first half of 2027.

What does a 41% lower risk of death mean?

The risk of death at any point was 41% lower in the vaccine group than in the control group: median survival of 24 months, against 14.7 months without it.

Feature Pakistan News Desk
Feature Pakistan News Desk
Feature Pakistan News Desk is the editorial team of Feature Pakistan, an independent digital news platform based in Pakistan. The desk reports national, world, business, sports, technology, health and education news, and every story is cross-checked against multiple sources before it is published. To reach the newsroom — including for corrections — email featurepakistanofficial@gmail.com or use the Contact page at featurepakistan.com/contact-us/.

opinion